vTv Therapeutics
VTVT
17 hedge funds and large institutions have $1.37M invested in vTv Therapeutics in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.
283% more capital invested
Capital invested by funds: $357K → $1.37M (+$1.01M)
1.99% less ownership
Funds ownership: 4.79% → 2.8% (-2%)
11% less funds holding
Funds holding: 19 → 17 (-2)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$163K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$92.9K |
| 3 |
Barclays
London,
United Kingdom
|
+$50.9K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$2.31K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$1.85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$37.1K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$19K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$13K |
| 4 |
Goldman Sachs
New York
|
-$12K |
| 5 |
Millennium Management
New York
|
-$10.5K |
VTVT Hedge Fund Activity: Q4 2018 in Review
17 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2018, worth a combined $1.37M — up 283% from $357K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VTVT and 4 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was D.E. Shaw & Co, opening a new position worth an estimated $163K. The largest seller was Panagora Asset Management, cutting an estimated $37.1K.
- 17 institutional investors held vTv Therapeutics (VTVT) as of Q4 2018, down from 19 in Q3 2018.
- Funds reported $1.37M of vTv Therapeutics stock for Q4 2018, up 283% quarter-over-quarter.
- 4 funds opened new vTv Therapeutics positions in Q4 2018 and 6 closed out, a net change of -2 holders.
- The largest vTv Therapeutics buyer in Q4 2018 was D.E. Shaw & Co, an estimated $163K added.
- The largest vTv Therapeutics seller in Q4 2018 was Panagora Asset Management, an estimated $37.1K sold.
Based on aggregated 13F filings for Q4 2018.